TRDA
Entrada TherapeuticsยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
TRDA Profile
Entrada Therapeutics, Inc.
A biopharmaceutical company that develops intracellular Endosomal Escape Vehicle therapeutics as a new class of medicines
One Design Center Place, Suite 17-500 , Boston, MA 02210
--
Entrada Therapeutics, Inc., was incorporated under the laws of the State of Delaware on September 22, 2016. The company aims to change the lives of patients by establishing endosomal escape vector (EEV) therapy as a novel drug, and is committed to becoming the world's foremost intracellular therapy company. The company's EEV therapies are designed to address intracellular targets that have long been considered inaccessible and undruggable. Through its proprietary, highly versatile modular EEV platform, the company is building a strong portfolio of EEV therapeutic drug candidates designed to enable effective intracellular delivery of therapeutic agents in a variety of organs and tissues and improve therapeutic indices. The company believes that the potential success of early-stage projects can be translated into the effective development of other EEV therapeutic candidates and the ability to build a portfolio in rare diseases, immunology and oncology.
